CGEM News and Press, Cullinan Oncology Inc. From 06/28/23

2023-06-28 09:08:05 ET Summary Cullinan is an intriguing play in the biotech sector. The company hopes to have 6 assets in clinical studies by the end of 2023. Lead asset Zipalertinib recently entered a pivotal study in EXON-20 mutated NSCLC - potentially a $1bn per annum mark...

2023-06-09 16:07:00 ET Shares of Cullinan Oncology (NASDAQ: CGEM) were up as much as 24.3% this week after being as high as 24.9%, according to data provided by S&P Global Market Intelligence . The stock closed last week at $10.53 and rose to as high as $13.40 on Thursday. C...

2023-05-26 12:36:09 ET Cullinan Oncology ( NASDAQ: CGEM ) rose ~8% on Friday after the biotech announced Phase 1 data for its solid tumor candidate CLN-619 indicating a complete remission and a favorable safety profile in a late-line setting. In addition to one complete resp...

CLN-619 demonstrated monotherapy activity across a range of tumor types, including in patients whose cancer had progressed on checkpoint inhibitor therapy Initial data indicate an acceptable safety profile of CLN-619 across all doses assessed Based on observed clinical activity in...

2023-05-11 17:03:21 ET Cullinan Oncology press release ( NASDAQ: CGEM ): Q1 GAAP EPS of -$1.42. Cash, cash equivalents, investments, and interest receivable were $503.5 million as of March 31, 2023. For further details see: Cullinan Oncology GAAP EPS of -$1.42

Zipalertinib pivotal trial now enrolling at the 100mg BID dose only First clinical data for CLN-049 and CLN-619 to be reported at EHA 2023 Congress and ASCO 2023 Annual Meeting, respectively Cash and investment position of $503.5 million as of March 31, 2023 continues to give runw...

CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that the first clinical data from its Phase 1 clinical study of CLN-619 in patients with adva...

CAMBRIDGE, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that its President and Chief Executive Officer, Nadim Ahmed, will p...

2023-04-05 01:28:51 ET Summary Cullinan has one partnered lead asset and other early stage programs. The company is trading way below cash, which often means the market thinks the company lacks growth prospects. This fact, contrasted with the strong data, makes Cullinan compli...

2023-03-27 14:17:01 ET Cullinan Oncology ( NASDAQ: CGEM ) announced Monday that the FDA cleared its Investigational New Drug (IND) application for cancer therapy CLN-617, marking the second such regulatory action to favor the company this year. Designed to function in the ...